Navigation Links
YM BioSciences enrolls first US patient in Phase II randomized, double-blind brain metastases trial for nimotuzumab
Date:5/27/2010

ctively target cancer cells resulting in improvements to the safety profiles of antibodies and the consequent prospect of their conjugation to highly potent toxins for safe delivery to tumour tissue. YM is also developing AeroLEF for the treatment of moderate to severe acute pain. The product is differentiated from other approaches using opioids because patients are able to individually control the analgesia required for their differing intensities of pain. AeroLEF has met all endpoints in each of its trials including a randomized Phase II trial and is currently being prepared for late-stage development internationally.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that nimotuzumab will continue to demonstrate a competitive safety profile in ongoing and future clinical trials; that JAK 1/2 and the VDA molecule will generate positive efficacy and safety data in future clinical trials; AeroLEF(R) will continue to generate positive efficacy and safety data in future clinical trials; and that YM and its various partners will complete their respective clinical trials within the timelines communic
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Regado Biosciences, Inc. Continues to Expand Its Patent Portfolio By Announcing Issuance of a New Patent for Its Product Candidates, the REG1 and REG2 Anticoagulation Systems
2. Sangamo BioSciences and Collaborators Present Data in Fifteen Presentations Highlighting Broad Therapeutic Applications of ZFP Technology
3. YM BioSciences announces presentations on global nimotuzumab trials at ASCO annual meeting
4. YM BioSciences third quarter 2010 operational and financial results
5. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
6. Regado Biosciences to Present at the BIO International Convention Held in Chicago, Illinois on May 5, 2010
7. YM BioSciences announces controlled equity offering
8. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2010 Financial Results
9. NeoStem, Inc. and ImmuneRegen BioSciences(R) Announce a Collaborative Agreement to Advance Stem Cell Technology
10. Neurocrine Biosciences, Inc. Announces Exercise of Over-Allotment Option for Common Stock Offering
11. YM BioSciences announces AACR acceptance of two nimotuzumab poster presentations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... China Cord Blood Corporation (NYSE: CO ... provider of cord blood collection, laboratory testing, hematopoietic stem ... that the Company has been informed that Magnum Opus ... by Mr. Yuen Kam, chairman of the board of ... (the "Shares") of  Excellent China Healthcare Investment Limited ("KKR ...
(Date:8/26/2015)... ... August 26, 2015 , ... PRC Clinical, ... new business relationships with local sponsors in southern California. The Clinical Trial Management Expert ... development processes and regulatory pathways., , Stem Cell Meeting ...
(Date:8/25/2015)... UK (PRWEB) , ... August 25, 2015 , ... ... determining whether breast tissue lesions are cancerous is described by University of Illinois ... international society for optics and photonics. , In “ Breast cancer diagnosis using ...
(Date:8/25/2015)... ... August 25, 2015 , ... One of the world’s foremost authorities on ... Bindiya Vakil, has been on a mission for the past two weeks. She’s been ... operations - from the two massive explosions that occurred on August 12 at the ...
Breaking Biology Technology:China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 2China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 3PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 2PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 3New Optical Method Promises Faster, More Accurate Diagnosis of Breast Cancer 2New Optical Method Promises Faster, More Accurate Diagnosis of Breast Cancer 3New Optical Method Promises Faster, More Accurate Diagnosis of Breast Cancer 4Resilinc Supply Chain Expert Warns: Impact of Tianjin Chemical Explosions Will be Far Worse than Reported 2Resilinc Supply Chain Expert Warns: Impact of Tianjin Chemical Explosions Will be Far Worse than Reported 3Resilinc Supply Chain Expert Warns: Impact of Tianjin Chemical Explosions Will be Far Worse than Reported 4
... note: Recently the Wisconsin Technology Network sat down ... Technology Council , to discuss the basic tenets of ... forth to help Wisconsins technology space grow. Read Part ... What are the biggest challenges the Wisconsin Technology Council ...
... are born with talent and everywhere it is in chains. ... fail Britain. Talent is 21st century wealth. This quotation is ... UK, in 1999. It opens chapter one of The Mismanagement ... British HR researchers Anthony Hesketh, Phillip Brown and Sara Williams. ...
... My fathers slow retreat in the face of Alzheimers Disease was ... was slow, at first, but gathered momentum over time. Independence turned ... fine physical shape for a man of 80, but his memory ... or two was gone. His body simply forgot how to function. ...
Cached Biology Technology:WTN exclusive interview with Tom Still, Wisconsin Technology Council - Part 2 2WTN exclusive interview with Tom Still, Wisconsin Technology Council - Part 2 3WTN exclusive interview with Tom Still, Wisconsin Technology Council - Part 2 4Talent Mismanagement 2Talent Mismanagement 3The passing of Ronald Reagan, and other Americans, is a reminder of the promise of stem-cell research 2
(Date:8/4/2015)... DUBLIN , Aug. 04, 2015 /PRNewswire/ ... ( http://www.researchandmarkets.com/research/nvh7k2/digital_forensics ) has announced the addition ... Component (Hardware, Software, and Service), Sub-Segment (Computer ... Cloud Forensics), Tool Types, Service, Vertical and ... report to their offering. By ...
(Date:7/31/2015)... SHENZHEN, China , 31 de julho de 2015 ... Genômica (ICG-10, www.icg-10.org ) será realizada pela BGI de ... China . A conferência está ... inauguração em 2006, a ICG se tornou uma das ... e um dos encontros científicos mais dinâmicos, entusiastas e ...
(Date:7/31/2015)... July 31, 2015 The 10 th International ... by BGI from October 22-25, 2015, in Shenzhen ... conference is celebrating its 10 th anniversary this year. Since ... world,s most influential annual meetings in the ,omics, fields, and ... gatherings. ICG-10 focuses on recent breakthroughs and ...
Breaking Biology News(10 mins):Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3The 10th International Conference on Genomics (ICG-10) to Open in October 2
... This release is available in German . , ... instead of acting straight away. However to be called a frog ... frogs are real winners at least from the point of ... terms of numbers frogs are superior to all the other amphibians, ...
... Ariz. Jan. 13, 2011 Genomic research could help ... cancer patients, according to a study by Genomic Health Inc. ... The drug, oxaliplatin, is widely used in colon cancer. It ... that are likely to recur. It is also used in ...
... bit of a Jekyll and Hyde relationship with mercury, ... National Laboratory have made a discovery that ultimately could ... known that microbes in aquatic environments make methylmercury, a ... they also know that nature and other types of ...
Cached Biology News:Inventions of evolution: What gives frogs a face 2TGen and Genomic Health Inc. discover genes affecting cancer drug 2Natural dissolved organic matter plays dual role in cycling of mercury 2
... mini incubation trays are disposable ... screen antigens that have been ... tray has eight 10.5 cm ... accommodate strips cut from blotted ...
... represents the state-of-the-art in permanent mounting ... permanent preservation of immunohistochemical organic insoluble ... Red, New Fuchsin, and any other ... tissue sections. Clarin can be used ...
... Gene Inspector can perform many sophisticated DNA analysis ... much more than just another sequence analysis product. ... suite of analyses to be performed each time ... custom style sheets which specify exactly how your ...
... Solid phase extraction through columns is a ... of applications. Typical applications are in DNA/RNA ... diagnostics, or compound purification in chemical or ... automated on the Genesis series instruments for ...
Biology Products: